Ignite Creation Date:
2024-05-06 @ 8:14 AM
Last Modification Date:
2024-10-26 @ 11:57 AM
Study NCT ID:
NCT02696356
Status:
COMPLETED
Last Update Posted:
2018-06-14
First Post:
2016-02-03
Brief Title:
Phase 1 Study of GRN-1201 in HLA-A02 Subjects With Resected Melanoma
Sponsor:
BrightPath Biotherapeutics
Organization:
BrightPath Biotherapeutics
Organization Data
Organization:
BrightPath Biotherapeutics
Class:
INDUSTRY
Study ID:
GRN1201-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
BrightPath Biotherapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None